Antibiotice Ia (ATB)
Bucharest Stock Exchange · Romania · prices in RON · close of 23 Oct 2026
Key indicators
| Last close | RON 1.966 |
|---|---|
| 52-week range | 1.752 – 2.590 |
| Return, 1 month / 3 months | +7.6% / −7.8% |
| Return, 1 year / 3 years | −19.9% / +74.2% |
| Trend | Below its 200-day average |
| RSI (14) | 51 |
| Volatility (1 year) | 24.1% |
| Worst drawdown (1 year) | -31.1% |
| Average daily value traded | 0.20M RON |
| Dividend yield | 1.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Antibiotice Iasi is a Romanian pharmaceutical manufacturer based in the city of Iasi. It develops and produces generic medicines, with a focus on antibiotics and other prescription drugs, and it also makes ointments and other topical treatments. Its customers are mainly hospitals, pharmacies and distributors in Romania and in export markets. The company operates its own manufacturing facilities and sells under its own brands as well as supplying active substances and finished products to partners.
Antibiotice Ia trades under the code ATB on the Bucharest Stock Exchange in Romania, with its price quoted in Romanian lei (RON). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Antibiotice Ia (ATB) trades on the Bucharest Stock Exchange in Romania. It last closed at RON 1.966 on 23 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 72 of 122 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 19.9% and over the last three months it fell 7.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Bucharest Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 28 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -3.0% | ||
| From 52-week high | -23.7% | ||
| Momentum | 32 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -7.8% | ||
| 6-month return | 10.6% | ||
| 12-month return, skipping the last month | -25.6% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 24.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -31.1% | ||
| Liquidity | 78 · Strong | Trades actively. | |
| Average daily value traded | 0.20M RON | ||
| Zero-volume days | 0.0% | ||
| Income | 46 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.8% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | −3.4% |
|---|---|
| 1 month | +7.6% |
| 3 months | −7.8% |
| 6 months | +10.6% |
| 1 year | −19.9% |
| 3 years | +74.2% |
| 5 years | +268.0% |
Signals
| 50-day / 200-day average | 1.950 / 2.028 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.049 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Oct 2026 | RON 0.0358 |
| 25 Sep 2025 | RON 0.0206 |
| 23 Sep 2024 | RON 0.0829 |
| 12 Sep 2023 | RON 0.0079 |
| 12 Sep 2022 | RON 0.0032 |
| 2 Sep 2021 | RON 0.0033 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Bucharest Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.